Search research articles
Contact Us
Filters
Showing results (561-570 of 627) with videos related to
Page
of 63
Sort By:
Human Mutation
|
January 16, 2007
Townes-Brocks syndrome: twenty novel SALL1 mutations in sporadic and familial cases and refinement of the SALL1 hot spot region
Elke M Botzenhart, Gabriella Bartalini, Edward Blair, et al.
Science Translational Medicine
|
July 17, 2024
Vasohibin inhibition improves myocardial relaxation in a rat model of heart failure with preserved ejection fraction
Deborah M Eaton, Benjamin W Lee, Matthew A Caporizzo, et al.
Cancer
|
April 1, 1983
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone
G P Murphy, S Beckley, M F Brady, et al.
The Journal of Urology
|
May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer
S A Loening, S Beckley, M F Brady, et al.
Journal of Surgical Oncology
|
June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
R P Gibbons, S Beckley, M F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Medicinal Chemistry
|
February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support
S F Brady, K J Stauffer, W C Lumma, et al.
Journal of Medical Genetics
|
November 1, 2022
The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in <i>BRCA1</i> and <i>BRCA2</i>
Sue Philpott, Maria Raikou, Ranjit Manchanda, et al.
Page
of 63
Search research articles
Search
Showing results (561-570 of 627) with videos related to
Sort By:
Page
of 63
Human Mutation
|
January 16, 2007
Townes-Brocks syndrome: twenty novel SALL1 mutations in sporadic and familial cases and refinement of the SALL1 hot spot region
Elke M Botzenhart, Gabriella Bartalini, Edward Blair, et al.
Science Translational Medicine
|
July 17, 2024
Vasohibin inhibition improves myocardial relaxation in a rat model of heart failure with preserved ejection fraction
Deborah M Eaton, Benjamin W Lee, Matthew A Caporizzo, et al.
Cancer
|
April 1, 1983
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone
G P Murphy, S Beckley, M F Brady, et al.
The Journal of Urology
|
May 1, 1983
Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer
S A Loening, S Beckley, M F Brady, et al.
Journal of Surgical Oncology
|
June 1, 1983
The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate
R P Gibbons, S Beckley, M F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Medicinal Chemistry
|
February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support
S F Brady, K J Stauffer, W C Lumma, et al.
Journal of Medical Genetics
|
November 1, 2022
The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in <i>BRCA1</i> and <i>BRCA2</i>
Sue Philpott, Maria Raikou, Ranjit Manchanda, et al.
Page
of 63